Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Artemisinin combination therapy (ACT) with artemether lumefantrine (AL) is currently the
first line treatment policy in Tanzania. AL is an efficacious drug that also has the capacity
to reduce malaria transmission to mosquitoes. Nevertheless, there is concern about the
development of parasite resistance against AL and there have been very few clinical trials
that compared different ACT regimens. A recent clinical trial shows that the combination of
dihydroartemisinin-piperaquine (DP) may be more efficacious than AL and may have a more
pronounced beneficial effect on post-treatment malaria transmission. Screening for molecular
markers that are related to parasite susceptibility to ACT drugs and to post-ACT treatment
malaria transmission can assist in preventing the development and spread of ACT resistance.
In the current study, the investigators compared AL and DP for the treatment of uncomplicated
malaria. The investigators endpoints are
- clinical efficacy
- post-treatment gametocytaemia by molecular techniques
- post-treatment malaria transmission.
Phase:
N/A
Details
Lead Sponsor:
Radboud University
Collaborators:
European Union Kilimanjaro Christian Medical Centre, Tanzania